Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) Gross Margin (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Gross Margin for 17 consecutive years, with 50.78% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 549.0% to 50.78% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 50.86% through Dec 2025, down 391.0% year-over-year, with the annual reading at 50.86% for FY2025, 391.0% down from the prior year.
  • Gross Margin hit 50.78% in Q4 2025 for Integra Lifesciences Holdings, down from 51.48% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 62.83% in Q4 2022 to a low of 50.37% in Q2 2025.
  • Historically, Gross Margin has averaged 57.3% across 5 years, with a median of 57.07% in 2023.
  • Biggest five-year swings in Gross Margin: surged 265bps in 2022 and later plummeted -840bps in 2023.
  • Year by year, Gross Margin stood at 61.47% in 2021, then increased by 2bps to 62.83% in 2022, then decreased by -9bps to 57.05% in 2023, then dropped by -1bps to 56.27% in 2024, then dropped by -10bps to 50.78% in 2025.
  • Business Quant data shows Gross Margin for IART at 50.78% in Q4 2025, 51.48% in Q3 2025, and 50.37% in Q2 2025.